250 related articles for article (PubMed ID: 34942275)
1. Translating a radiolabeled imaging agent to the clinic.
Griffiths GL; Vasquez C; Escorcia F; Clanton J; Lindenberg L; Mena E; Choyke PL
Adv Drug Deliv Rev; 2022 Feb; 181():114086. PubMed ID: 34942275
[TBL] [Abstract][Full Text] [Related]
2. The Academic NDA: Justification, Process, and Lessons Learned.
Sunderland JJ
J Nucl Med; 2020 Apr; 61(4):480-487. PubMed ID: 32034112
[TBL] [Abstract][Full Text] [Related]
3. A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement.
Barrio JR; Marcus CS; Hung JC; Keppler JS
Mol Imaging Biol; 2004; 6(6):361-7. PubMed ID: 15564146
[TBL] [Abstract][Full Text] [Related]
4. INDs for PET molecular imaging probes-approach by an academic institution.
Mosessian S; Duarte-Vogel SM; Stout DB; Roos KP; Lawson GW; Jordan MC; Ogden A; Matter C; Sadeghi S; Mills GQ; Schelbert HR; Radu CG; Czernin J; Couto M; Phelps ME
Mol Imaging Biol; 2014 Aug; 16(4):441-8. PubMed ID: 24733693
[TBL] [Abstract][Full Text] [Related]
5. Regulatory Agencies and PET/CT Imaging in the Clinic.
Herscovitch P
Curr Cardiol Rep; 2022 Oct; 24(10):1361-1371. PubMed ID: 35913674
[TBL] [Abstract][Full Text] [Related]
6. [Molecular imaging-based early-phase and exploratory clinical research].
Watanabe Y
Yakugaku Zasshi; 2013; 133(2):187-95. PubMed ID: 23370512
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomographic imaging in drug discovery.
Ghosh KK; Padmanabhan P; Yang CT; Ng DCE; Palanivel M; Mishra S; Halldin C; Gulyás B
Drug Discov Today; 2022 Jan; 27(1):280-291. PubMed ID: 34332093
[TBL] [Abstract][Full Text] [Related]
8. 177Lu-Dotatate for midgut neuroendocrine tumours.
Burki TK
Lancet Oncol; 2017 Feb; 18(2):e74. PubMed ID: 28111117
[No Abstract] [Full Text] [Related]
9. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
Marchetti S; Schellens JH
Br J Cancer; 2007 Sep; 97(5):577-81. PubMed ID: 17726450
[TBL] [Abstract][Full Text] [Related]
10. NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):8-9. PubMed ID: 27168104
[No Abstract] [Full Text] [Related]
11. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.
Pfeifer A; Knigge U; Mortensen J; Oturai P; Berthelsen AK; Loft A; Binderup T; Rasmussen P; Elema D; Klausen TL; Holm S; von Benzon E; Højgaard L; Kjaer A
J Nucl Med; 2012 Aug; 53(8):1207-15. PubMed ID: 22782315
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Efficacy of Targeted Imaging Agents.
Graham MM; Weber WA
J Nucl Med; 2016 Apr; 57(4):653-9. PubMed ID: 26769867
[TBL] [Abstract][Full Text] [Related]
13. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
14. NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with
Hope TA; Abbott A; Colucci K; Bushnell DL; Gardner L; Graham WS; Lindsay S; Metz DC; Pryma DA; Stabin MG; Strosberg JR
J Nucl Med; 2019 Jul; 60(7):937-943. PubMed ID: 31263080
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement.
Sako T; Hasegawa K; Nishimura M; Kanayama Y; Wada Y; Hayashinaka E; Cui Y; Kataoka Y; Senda M; Watanabe Y
Biochem Biophys Res Commun; 2013 Dec; 442(1-2):79-84. PubMed ID: 24220338
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
[TBL] [Abstract][Full Text] [Related]
18. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.
Kroiss A; Putzer D; Uprimny C; Decristoforo C; Gabriel M; Santner W; Kranewitter C; Warwitz B; Waitz D; Kendler D; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):865-73. PubMed ID: 21279352
[TBL] [Abstract][Full Text] [Related]
19. Molecular Imaging in the Head and Neck: Diagnosis and Therapy.
Howard BA
Radiol Clin North Am; 2020 Nov; 58(6):1135-1146. PubMed ID: 33040853
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
